CDC Resources

  • Ending Isolation and Precautions for People with COVID-19: Interim Guidance
    This page is for healthcare professionals caring for people in the community setting under isolation with laboratory-confirmed COVID-19.
  • Quarantine and Isolation Calculator CDC
    A tool to help determine how long you need to isolate, quarantine, or take other steps to prevent spreading COVID-19.
  • COVID-19 Vaccine Boosters - CDC Guidance
    COVID-19 vaccine boosters can further enhance or restore protection that might have waned over time after your primary series vaccination. People are protected best from severe COVID-19 illness when they stay up to date with their COVID-19 vaccines, which includes a booster for many people. There are different COVID-19 vaccine recommendations for people who are moderately or severely immunocompromised.
  • Emergency Use Instructions for Healthcare Providers: Moderna COVID-19 vaccine for Primary, Additional, and/or Booster Doses
    The Centers for Disease Control and Prevention (CDC) is issuing Emergency Use Instructions (EUI) to provide information about the use of the COVID-19 vaccine by Moderna (Spikevax), which is approved (licensed) by the Food and Drug Administration (FDA) for the prevention of COVID-19 in individuals 18 years and older. 1 The CDC-issued EUI provide instructions and information for the use of this vaccine that are beyond the FDAapproved labeling. The CDC-issued EUI provide information on the following uses of the COVID-19 vaccine by Moderna for: • a longer interval of 4–8 weeks between the first and second primary dose of Moderna COVID-19 vaccine for persons 18 years and older, particularly for individuals at higher risk of mRNA COVID-19 vaccine-associated myocarditis. • primary dose(s) in those with certain immunocompromising conditions or those with incomplete primary dose series, and/or a booster dose for persons 18 years and older who received primary vaccination with certain non-FDA authorized or approved COVID-19 vaccines2 . • a 3-month interval for the booster dose after an mRNA vaccine primary series for persons 18 years and older who are moderately or severely immunocompromised. • an additional dose in persons 18 years and older with certain immunocompromising conditions who received primary vaccination with the Janssen COVID-19 Vaccine. • revaccination of moderately or severely immunocompromised persons 18 years and older who received certain therapies (i.e., hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)- T-cell therapy) and received dose(s) of COVID-19 vaccine prior to or during treatment.
  • Clinical Guidance for COVID-19 Vaccination – CDC
    Summary of recent changes (last updated April 21, 2022): Added considerations for the option to receive a second COVID-19 vaccine booster dose Updated guidance for COVID-19 vaccination after SARS-CoV-2 infection
  • How to Use Your N95 Respirator – CDC
    N95s must form a seal to the face to work properly. This is especially important for people at increased risk for severe disease. Wearing an N95 can make it harder to breathe. If you have heart or lung problems, talk to your doctor before using an N95.
  • Stay Up to Date with Your COVID-19 Vaccines
    CDC recommends that everyone ages 5 years and older get their primary series of COVID-19 vaccine, and everyone ages 12 years and older also receive a booster. Some people can receive two boosters. People who are moderately or severely immunocompromised have specific COVID-19 vaccine recommendations, including recommendations for a booster. Learn more about COVID-19 vaccine recommendations for people who are moderately or severely immunocompromised. Use CDC’s COVID-19 Booster Tool to learn if and when you can get boosters to stay up to date with your COVID-19 vaccines. The following COVID-19 vaccine and booster recommendations may be updated as CDC continues to follow data related to vaccine effectiveness and safety, waning immunity, and protection against variants.
  • Prioritizing Case Investigation and Contact Tracing for COVID-19
    These recommendations are intended to assist state, tribal, local, and territorial (STLT) health departments prioritize COVID-19 case investigation and contact tracing activities.
  • Case Investigator’s Interview Tool: Talking with People About COVID-19
    Universal case investigation and contact tracing are not recommended. This tool can be used to interview priority cases.
  • Contact Tracer’s Interview Tool: Notifying People About an Exposure to COVID-19
    Universal case investigation and contact tracing are not recommended. This tool can be used to notify priority close contacts.

HHS Resources

  • AHRQ Best Practice Summaries
    These resources are designed to help nursing homes consider best practices on topics such as infection control and prevention and the emotional well-being of both staff and residents.
  • Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    The Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease (AD) when furnished in accordance with Section B (Coverage Criteria) under coverage with evidence development (CED) for patients who have: A clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
  • QSO-22-15-NH & NLTC & LSC – Update to COVID-19 Emergency Declaration Blanket Waivers for Specific Providers
    CMS continues to review the need for existing emergency blanket waivers issued in response to the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (PHE). • Over the course of the COVID-19 PHE, skilled nursing facilities/nursing facilities (SNFs/NFs), inpatient hospices, intermediate care facilities for individuals with intellectual disabilities (ICF/IIDs), and end-stage renal disease (ESRD) facilities have developed policies or other practices that we believe mitigates the need for certain waivers. • Applicable waivers will remain in effect for hospitals and critical access hospitals (CAH). • CMS will end the specified waivers in two groups: o 60 days from issuance of this memorandum o 30 days from issuance of this memorandum
  • CMS 2019-Novel Coronavirus (COVID-19) Medicare Provider Enrollment Relief Frequently Asked Questions (FAQs)
    CMS released Frequently Asked Questions on Medicare Provider Enrollment Relief related to COVID-19 including the toll-free hotlines available to Medicare Administrative Contractors (MACs). CMS has established toll-free hotlines at each MAC to allow physicians and non-physician practitioners to initiate temporary Medicare billing privileges. These hotlines provide expedited enrollment and answer questions related to COVID-19 enrollment requirements.
    You must log in to access content.
  • AHRQ Toolkit for Decolonization of Non-ICU Patient with Devices
    This toolkit can help hospital infection prevention programs implement a decolonization protocol that was found to reduce bloodstream infections by more than 30 percent in adult inpatients who were not in intensive care units (ICUs) and who had specific medical devices. It includes implementation instructions, demonstration videos, and customizable tools.
    You must log in to access content.
  • ASPR The Express Newsletter: Mrch 2022 (Update #2)
    This issue of The Express highlights the following resources: Strategies for Healthcare Workplace Violence Prevention: Risk Assessment and De-Escalation (Webinar) Workplace Violence Topic Collection (Updated) Trends, Policies, and Protocols Related to Healthcare Workplace Violence ASPR TRACIE Reaches 10,000 Technical Assistance (TA) Requests! Closing the COVID-19 Test to Treatment Gap (Webinar) ASPR TRACIE at AHEPP Annual Virtual Conference CBRN Resources Comments Requested on 2023-2026 National Health Security Strategy
    You must log in to access content.
  • SAMHSA’s Concept of Trauma and Guidance for a Trauma-Informed Approach
    This manual introduces a concept of trauma and offers a framework for becoming a trauma-informed organization, system, or service sector. The manual provides a definition of trauma and a trauma-informed approach, and offers 6 key principles and 10 implementation domains.

NIH Resources

  • NIH - Testing for SARS-CoV-2 Infection
    Everyone who has symptoms that are consistent with COVID-19 and people with known high-risk exposures to SARS-CoV-2 should be tested for SARS-CoV-2 infection. Such testing should employ either a nucleic acid amplification test (NAAT) or an antigen test to detect SARS-CoV-2. Testing may also be used for screening, determining the length of a patient’s isolation period, and other nondiagnostic purposes.
  • COVID-19 Treatment Guidelines – What’s New in the Guidelines
    The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines is published in an electronic format that can be updated in step with the rapid pace and growing volume of information regarding the treatment of COVID-19. The COVID-19 Treatment Guidelines Panel (the Panel) is committed to updating this document to ensure that health care providers, patients, and policy experts have the most recent information regarding the optimal management of COVID-19 (see the Panel Roster for a list of Panel members). New Guidelines sections and recommendations and updates to existing Guidelines sections are developed by working groups of Panel members. All recommendations included in the Guidelines are endorsed by a majority of Panel members (see the Introduction for additional details on the Guidelines development process). Major revisions to the Guidelines within the past month are as follows:
  • Pain Assessment in Hospitalized Older Adults with Dementia and Delirium
    Pain can have negative effects leading to prolonged hospital stays. Determining the presence of uncontrolled and untreated pain in patients with cognitive impairments such as delirium, dementia, and delirium superimposed on dementia (DSD) is challenging. One tool commonly suggested for use in assessment of pain in older adults with cognitive impairment is the Pain Assessment In Advanced Dementia (PAINAD) scale. Proper use of the PAINAD scale as part of a comprehensive pain management plan can help reduce the likelihood of a patient experiencing unrecognized and untreated pain. Using an individual example, this article illustrates best practices in pain assessment and management for a woman experiencing DSD during an acute hospitalization.

Other Outside Resources

  • Stopping the Spread of RSV
    A Toolkit for Educating and Engaging Residents of Long-Term Care Facilities
  • MDHHS COVID-19 Vaccination Schedule For Those who are Moderately or Severely Immunocompromised
    COVID-19 Vaccine timeline for people who are moderately or severely immunocompromised, including 2nd booster dose.
  • MDHHS COVID-19 Vaccination Schedule
    COVID-19 Vaccine timeline including 2nd booster dose.
  • EUA of the Moderna COVID-19 Vaccine Fact sheet for Primary Series and Booster Dose Presentation
    This Fact Sheet pertains only to Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border which is authorized for use to provide:  * a two-dose primary series to individuals 18 years of age and older;  * a third primary series dose to individuals 18 years of age and older with certain kinds of immunocompromise;  * a first booster dose to individuals 18 years of age and older who have completed a primary series with Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA);  * a first booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination;  * a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine; and  * a second booster dose to individuals 18 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine.
  • EUA of the Moderna COVID-19 Vaccine Fact sheet for Booster Dose Only
    This Fact Sheet pertains only to Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a dark blue cap and a label with a purple border which is authorized for use to provide:  * a first booster dose to individuals 18 years of age and older who have completed a primary series with Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA); * a first booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination;  * a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine; and * a second booster dose to individuals 18 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine.
  • Caring for the LGBTQ+ Population Special Report - IASC
    According to the American Psychological Association, “more than 39 million people in the U.S. are age 65 years or older, including 2.4 million people who identify as lesbian, gay, sexual, or transgender (LGBT).” This population is only expected to grow as the American population ages. SAGE Advocacy & Services for LGBT Elders, a national advocacy and service organization that has supported LGBT elders since 1978, estimates that by 2030, there will be about 7 million adults over age 50 in the U.S. who identify as LGBT. Although some LGBTQ+ Boomers were able to come out as attitudes liberalized, not all did. And many of these adults have now become seniors who need care. Their needs may be more significant than and different from those of people who identify as cisgender or heteronormative. In comparison to their heterosexual peers, this group typically faces significant economic and health disparities. SAGE reports that LGBT seniors are “twice as likely to be single and live alone.” They’re also “four times less likely to have children,” and “far more likely to have faced discrimination and social stigma.” They are also more likely to face poverty and homelessness and to be in poor health. All of these factors can make planning for and engaging in appropriate care in their later years more difficult. In this report, we’ll explore some ways you can make your facility more welcoming and inclusive to all seniors, including those who identify as LGBTQ+.
  • OIG - Telehealth Was Critical for Providing Services to Medicare Beneficiaries During the First Year of the COVID-19 Pandemic
    Beneficiaries’ use of telehealth increased dramatically during the first year of the pandemic. Over 28 million—more than 2 in 5—Medicare beneficiaries used telehealth services during the first year of the pandemic, from March 2020 through February 2021. In total, beneficiaries used 88 times more telehealth services during the first year of the pandemic than they did in the prior year. Beneficiaries’ use of telehealth was particularly high in April 2020, when it accounted for 29 percent of all services. It then decreased to around 10 percent of services per month—still almost twice the level it was in March 2020. In addition, beneficiaries most commonly used telehealth for office visits, but their use of telehealth for behavioral health services stands out. Beneficiaries used telehealth for a larger share of their behavioral health services compared to their use of telehealth for other services.
  • Social Isolation Among Older Adults During the Pandemic
    This report by Federal, Provincial and Territorial Forum of Ministers Responsible for Seniors (Canada) investigates how the COVID-19 pandemic has affected older Canadians, focusing on social isolation and loneliness.
  • Management of Paxlovid drug-drug-interactions
    University of Michigan Medicine list of Paxlovid drug-drug-interactions.
  • Frequently Asked Questions on the Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cligavimab) for Pre-exposure Prophylaxis (PrEP) of COVID-19
    This report distills three key trends that present opportunities for developing more efficient Medicare spending and improved PAC utilization: